The INK4a-ARF (CDKN2A)-locus on chromosome 9p21 encodes for two tumour suppressor proteins, p16 INK4a 
, p16
INC4a and p53. After microdissection, DNA of 71 hepatocellular carcinomas was analysed for INK4-ARF inactivation and p53 mutation by DNA sequence analysis, methylation-speci®c PCR (MSP), restriction-enzyme related polymerase chain reaction (RE ± PCR), mRNA expression and immunohistochemistry. In addition, microdeletion of p14 ARF and p16 INC4a were assessed by dierential PCR. Inactivation of p14 ARF was found in 11/71 cases (15%), alterations of p16
INK4a occurred in 47/71 carcinomas (66%), which correlated with loss of mRNA transcription. Five tumours (7%) had homozygous deletions of the INK4a-ARF locus. We failed to detect speci®c mutations of both exons. P16
INK4a methylation with an unmethylated p14 ARF promotor appeared in 39 cases. Mutations of p53 were found in 30 of 71 HCC (42%), and only one of them harboured p14 ARF inactivation. We failed to establish alterations of the INK4a-ARF locus or p53 status as independent prognostic factor in these tumours. Our data indicate, that p14 ARF methylation occurs independently of p16
INK4a alterations in a subset of HCC together with wild type p53. The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative eects in hepatocarcinogenesis. Oncogene (2001) INK4a and p14 ARF , both involved in cell-cycle regulation (Roussel, 1999) . The two proteins are characterized by two distinct promotors and ®rst exons spliced to a common exon 2 in dierent reading frames: exon 1a, 2 and 3 for p16 INK4a and exon 1b, 2 and 3 for p14 ARF (Bradley et al., 2001) . The p16
INK4a
gene is inactivated by mutations, homozygous deletions, or gene methylation in many tumours of diverse origin (Baylin and Herman, 2001 ). P14
ARF has been shown to function as a growth suppressor by speci®cally activating the p53 pathway. Induction of p14 ARF (in response to an oncogenic signal such as c-myc, activated ras) leads to the localization and sequestration of MDM2 in the nucleolar compartment, thereby stabilizing p53 by preventing MDM2-p53 from undergoing ubiquitinmediated degradation (deToledo et al., 2000) . Thus, it has been suggested, that concomitant p14 ARF and p53 gene inactivation must be rare events in the same tumour (Matsuda et al., 1999; Fulci et al., 2000) .
To gain insights into the role of the INK4a-ARF locus in the carcinogenic process of hepatocellular carcinomas, mutational analyses of the p16 INK4a , p14 ARF and the p53 gene were performed in 71 patients with this disease.
After microdissection, the methylation status of the INK4a-ARF locus was determined using two dierent methods ± MSP analysis as well as RE ± PCR (Figure 1a ± c) (Baur et al., 1999 , Chaubert et al., 1997 Esteller et al., 2000 , Tannapfel et al., 2000 .
Using these two methods, promotor methylation of p14 ARF was present in 6/71 cases (9%). In all patients, corresponding non-neoplastic liver tissue was also analysed; no p14 ARF promotor methylation was observed in any case. The analysis of the methylation status of the adjacent p16
INK4a gene revealed, that 42 out of 71 carcinomas (59%) examined showed aberrant methylation at the 5'CpG island. Despite microdissection, ampli®cation of unmethylated templates were detected also to some degree, probably because of contaminated normal intratumourous tissue (®bro-blasts, endothelial cells, in¯ammatory cells) (Liew et al., 1999) . Thirty-eight patients exhibited a concomitant liver cirrhosis. Methylated p16
INK4a was observed in 12 of these patients (32%) (Figure 1a ± c) . These data are in accordance with those published by Kaneto et al. (2001) , who found a prevalence of p16 suggest that chronic in¯ammation (as it is observed in liver cirrhosis) is associated with high levels of methylation, perhaps as a result of increased cell turnover, and that cirrhosis can be viewed as resulting in`premature ageing' of hepatocytes (or liver myo®-broblasts and sinusoidal cells). The hypothesis is underlined by Issa et al. (2001) , who reported on an accelerated age-related CpG island methylation in ulcerative colitis (Issa et al., 2001) , the same observation was recently published in patients with atrophic gastritis (Kang et al., 2001) .
In (Figure 1e ). In the 29 cases shown to lack p16 INK4a promotor methylation, nuclear staining of p16 protein was observed in nearly all tumour cells with a moderate to strong intensity of immunoreactivity. In normal liver tissue, p16 protein was detected in nearly all cases (Figure 1f) .
To compare the relative levels of p16 INK4a and p14 ARF mRNA, multiplex RT ± PCR was performed ( Figure 1d ). Using speci®c sense primers for exon 1a and exon 1b and a common reverse primer for exon 2, both transcripts were simultaneously ampli®ed in a single reaction. p16
INK4a mRNA was ampli®ed in 29/71 cases, p14 ARF transcripts were detected in 60/71 tumours ( Figure 1d ). Among the tumours with downregulated p16
INK4a or p14 ARF mRNA, methylation of the corresponding promotors or complete loss of the 9p21 locus were observed in 29 and in 11 cases, respectively. We therefore conclude, that p14 ARF methylation is independent of p16 INK4a . Thus, the p14 ARF promotor demonstrates selective epigenetic silencing independent of that of p16
INK4a . The strong correlation between promotor methylation and transcriptional inactivation, as examined by multiplex RT ± PCR, indicates, that aberrant methylation is a major mechanism of inactivation of the INK4a-ARF locus.
To examine the INK4-ARF locus for microdeletion, a dierential PCR technique was applied using speci®c primers for exon 1b and exon 3. The allelic balance at these two exons was determined using the interferon-g gene as an internal allele dosage standard (Figure 2) . Additionally, microsatellite analysis with 12 highly polymorphic microsatellite markers¯anking the region of chromosome 9p21-23 was performed (Tannapfel et al., 2000) . Included were markers spanning exon 1a, 1b and 3 and introns 1a, 1b and 2 of INK4-ARF. The markers used were D9S1749, D9S1748, D9S157, D9S162, D9S161, D9S259, D9S270, D9S171, D9S1752, D9S256, D9S156, and IFN-a based on sequences in the Genome Database or obtained from Research Genetics (Huntsville, AL, USA).
Seventy normal/tumour pairs could be interpreted for allelic dosage analysis (Tables 2 and 3; Figure 2 ). The two genes, p14 ARF and p16 INK4a were found concomittantly deleted in ®ve patients. Hemizygous loss was observed in ®ve cases. No exclusive loss of either p16
INK4a or p14 ARF was found in our tumours. Immunohistochemistry showed no speci®c p16
INK4a or p14 ARF protein staining in cases with homozygous deletion. We failed to establish a signi®cant relationship between stage and grade of disease or concomit-tant cirrhosis and allelic loss. Taken together, in accordance with data reported for colon cancer (Esteller et al., 2000; Dai et al., 2000) , our results indicate that promotor methylations rather than deletions of the INK4a-ARF locus play a major role in tumorigenesis of hepatocellular carcinoma.
Mutations of exons 1 and 2 of the INK4a-ARF gene were analysed by SSCP ± PCR followed by direct sequencing of the cases with anomalous migrating bands. In 12 cases, abnormal bands were visible. However, we failed to detect speci®c mutations within both exons. In one case, a polymorphism was identi®ed (C.442G4A; A148T).
To analyse the relation of INK4a-ARF alterations and p53 mutations, mutational analysis of exon 5 to 9 of the p53 gene was performed.
p53 mutations were detected in 30 cases (42%). Prevalence and the mutation pattern observed are comparable with previously published data (Jackson et al., 2001) (Table 2) . Decoding the tumour samples by their p53 status, revealed p14 ARF methylation in one out of 30 cases with mutated p53 and in ®ve of 41 cases , and p53 in three hepatocellular carcinomas (case no 1, 24 and 66; same patients as in Table  3 ). (a) p14
ARF and p16 INK4a analysis with RE ± PCR. Genomic DNA was digested with four methyl-sensitive (HpaII, NaeI, EaglI and Ksp1) and with one non-methyl-sensitive (MspI) restriction enzyme. PCR ampli®cation of a 316-bp fragment of p14 ARF exon 1 containing one HpaII and one Ksp1 site were ampli®ed by PCR. The following primers were used: forward: GCCTGCGGGGCGGAGAT; reverse: GCGGCTGCTGCCCTAGA. For p16
, a 150 bp fragment of exon 1 containing two HpaII and one Ksp1 site were ampli®ed by PCR. The primer sets were GGGAGCAGCATGGAGCCG (forward) and CTGGATCGGCCTCCGACCGTA (reverse). Undigested placental and tumour DNA was used as control. Cases were considered as positive by RE ± PCR, when PCR ampli®cation was obtained after digestion with one of the methyl-sensitive restriction enzymes used (a,b). The methyl-sensitive restriction enzymes used for RE ± PCR are indicated (HpaII, KspI) digestion with the non-methylsensitive enzyme MspI serves as a negative control; undigested DNA (control) serves as a positive control. The p14 ARF gene is methylated in case 24 and unmethylated in case 1 and 66. (b) p16
INK4a analysis with RE ± PCR. Like a, the methyl-sensitive restriction enzymes used for RE ± PCR are indicated (HpaII, KspI) digestion with the non-methyl-sensitive enzyme MspI serves as a negative control; undigested DNA (control) served as a positive control. Methylation of p16
INK4a is detected in case 1, but not in case 24 and 66. (c) p16
INK4a analysis using MSP. Bisul®te-treated DNA (which changes the unmethylated but not the methylated cytosines into uracil) is subjected to PCR ampli®cation using primers designed to anneal speci®cally to the methylated bisul®te-modi®ed DNA. MSP results are expressed as unmethylated p16-speci®c bands (U) or methylated p16-speci®c bands (M). Bisul®te-converted DNA from normal corresponding liver tissue (N) served as a negative control as indicated by the presence of the U but not the M band. In concordance to b, methylation of p16
INK4a is detected in case 1, but not in case 24 and 66. (d) Multiplex RT ± PCR. To compare the relative p16
INK4a and p14 ARF mRNA, multiplex RT ± PCR was performed. Two mg of total RNA was subjected to reverse transcription reaction using random oligonucleotide primers and superscript II reverse transcriptase (GIBCO BRL, Rockville, MD, USA). One ml of the RT reaction product was then ampli®ed by PCR using the forward primers of exon 1a and 1b and the reverse primer for exon 2 of the p16
-p14 ARF gene. The primers were as follows: forward exon 1a (sense 1): 5'-GCTGCCCACGCACCGAATA-3'; exon 1b (sense 2): 5-'CCCTCGTGCTGATGCTACTGA-3'; and reverse primer (antisense) 5-'ACCACCAGCGTGTCCAGGAA-3'. Hot start PCR was performed for 35 cycles (958C for 45 s; 578C for 45 s, and 728C for 60 s). The size of the products were 179 bp for p16
INK4a and 200 bp for p14 ARF , respectively. Results of Multiplex-RT ± PCR of p14 mRNA (upper line, indicated by blue, corresponding to 200 bp) and p16 mRNA (lower line, indicated by green, corresponding to 179 bp) for case no 1, 24 and 66. (e) Immunostaining of p16
INK4a protein in hepatocellular carcinomas performed as described previously (Tannapfel et al., 1999) . Case 1 with methylated p16
INK4a and a complete loss of p16 harbouring wild type p53. In 31 HCC neither p53 nor p14 ARF alterations (including methylation and deletion) were observed. Therefore, tumours with wild type p53 harbour p14 ARF alterations signi®cantly more often than those with a mutated p53 (P 50.05). Ten patients (14%) displayed neither INK4a-ARF nor p53 alterations.
Of the 47 HCC with an inactivated p16
INK4a gene, 22 also had a mutated p53, whereas 25 carcinomas were identi®ed with a wild type p53 gene. Furthermore, eight patients with mutated p53 exhibited an unaltered p16 INK4a gene. In 16 patients, neither p16 INK4a nor p53 alterations were found. Ten out of 71 (14%) of our Figure 2 Allelic dosage analysis of p14 ARF and p16
INK4a
. Allelic dosage analysis for the p14 ARF and p16 INK4a genes were performed using dierential PCR. DNA fragments were ampli®ed in exon 1b of p14 ARF , exon 3 of p16 INK4a and exon 2 using the following primers: p14arf exon 1b: ARF2F 5'-CTCGTGCTGATGCTACTAGAG-3' and ARF2R 5'-AAGTCGTTGTAACCC-GAATG-3', p16 exon 3: p16ex3F: 5'-CGATTGAAAGAACCAGAGAG-3' and p16ex3R 5'-ATGGACATTTACGGTAGTGG-3' interferon-g: INFGF2dF 5'-GCAGGTCATTCAGATGTAGC-3' and INFG2RdR 5'-AGAGCACAAACAGAGGATGA-3'. Results of dierential PCR technique as described in the text. Negative control: LNZ343 with a known deletion of the INK4a-ARF locus. Positive controls: HepG2 with an intact INK4-ARF locus. The ratio of DNA fragment intensity in HepG2 between exon 1b or exon 3 and the internal control ifn-g was used to normalize the results. Hemizygous deletion was diagnosed, if the ratio of the tumour sample was 50% of the one found in HepG2 (patient no 12). If the ratio was less than 40%, the tumour sample was considered to harbour a homozygous deletion (patient no 4). In patient no 32, 33, 40 the ratio between exon 1b or exon 3 and the ifn-g was 70 ± 100% of the ratio found in HepG2, suggesting that there was no loss at the INK4a-ARF locus tumours examined were identi®ed with both an intact INK4a-ARF locus and also wild type 53. Therefore, our data indicate that, at least in hepatocellular carcinoma, inactivation of p14 ARF could be restricted to tumours with wild type p53. Thus, the loss of p14 ARF and mutations of p53 could be mutually exclusive events, suggesting that they may be functionally equivalent in hepatocarcinogenesis. For p16 INK4a methylation, no such correlation was found. Taken together, the p53-pathway was disrupted either by Finally, we looked for a possible prognostic signi®cance of INK4a-ARF alterations and p53 in our tumours. Survival analysis with the following variables was performed: INK4a-ARF status, p53 and UICC tumour stage (UICC 1997), grading, vascular invasion, multiplicity, satellites, dysplasia, in¯ammatory reaction, necrosis, and patient's age.
As expected, UICC stage, and histological grade of tumour dierentiation (Edmondson Grading), were signi®cant prognostic parameters in univariate analysis. Neither INK4a-ARF alterations nor p53 were related to the prognosis of our patients examined. Performing multivariate analysis, only Edmondson Grading had an independent prognostic impact. Therefore, INK4a-ARF alterations may not re¯ect the biological behaviour of HCC, as it was reported for other tumours (e.g. renal cell carcinomas, lymphomas (Orlow et al., 1999; Schraml et al., 2001) . However, this is the ®rst multivariate report of a possible prognostic impact of INK4a-ARF genes in hepatocellular carcinoma. Due to strict selection criteria (only cases with primary curative [R0-] resection were examined, patients receiving liver transplantation were excluded), only a limited number of cases were assessable for our study. Therefore, the actual prognostic value of p14 ARF and p16
INK4a should be examined in a larger group of patients.
In conclusion, our data suggest that promotor methylation appears to be the main cause of inactivation of the INK-ARF locus in hepatocellular carcinoma. The overall frequency of 9p21 alterations, including deletion and methylation, was 78%. Silencing of INK4a-ARF gene products ± coding for critical regulators of cell cycle progression ± is therefore one of the most frequent genetic defects in HCC.
Abbreviations HCC, hepatocellular carcinoma; MSP, methylation speci®c PCR; RE ± PCR, restriction enzyme-related PCR; LOG, loss of heterozygosity
